We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Siemens Spotlights Innovations and Trends in Clinical Diagnostics and Point-of-Care Testing

By LabMedica International staff writers
Posted on 21 Jul 2023
Print article
Image: The IMMULITE 2000 XPi immunoassay system (Photo courtesy of Siemens)
Image: The IMMULITE 2000 XPi immunoassay system (Photo courtesy of Siemens)

Siemens Healthineers (Erlangen, Germany) is highlighting its newest innovations and trends in clinical diagnostics and point-of-care testing at AACC 2023.

At the Siemens AACC 2023 booth, experts will provide a high-level overview of Atellica Integrated Automation. Powered for workflow and workforce efficiency, the company’s Atellica Solution delivers control and simplicity so labs can drive better outcomes. Experts will also demonstrate how the IMMULITE 2000 XPi immunoassay system can address common challenges faced by specialty laboratories. Providing multiple tests on a single, easy-to-use analyzer, the IMMULITE 2000 XPi immunoassay system makes it simple for labs to scale capabilities without disrupting regular day-to-day operations. It allows consolidation of routine and specialty testing, including allergy, on a single platform in labs with low to medium test volumes. Labs can incorporate specialty testing, including allergy, into routine workloads without interrupting the lab workflow in labs with medium to high test volumes.

Visitors to the Siemens booth at AACC 2023 also had the first view of the newly-launched Atellica CI Analyzer, a compact testing system designed to tackle lab challenges. The Atellica CI Analyzer1 for immunoassay and clinical chemistry testing is the newest addition to Siemens’ Atellica in vitro diagnostics portfolio. The Atellica CI Analyzer makes it possible for both standalone labs and satellite labs of wider health networks to have the same reagents, consumables, and intelligent software as the company's flagship Atellica Solution—now condensed into a 1.9 square meters footprint ideal for smaller laboratories. The Atellica CI Analyzer aims to address labor shortage pain points and drive revenue growth, fostering agility beyond standardization and clinical equivalence.

Siemens is also demonstrating how labs can leverage the power of open connectivity with POC informatics. With its POCcelerator Data Management System, labs can simplify their POCT workflows and dramatically reduce workload for their staff. All patient results, quality controls, operators, reagents, and device data can be collected and reviewed in a clear and structured format in order to comply with regulatory guidelines. In addition, Siemens is demonstrating the utility of its non-invasive tests such as the ELF Test in the NALFD/NASH patient referral pathway, alongside its advancements in VWD diagnostics for improved management of bleeding patients. Among its solutions for critical care testing, Siemens is showcasing its epoc Blood Analysis System that securely delivers critical testing results at the patient-side in less than one minute and connects the entire team, so it doesn’t matter if the laboratory staff and caregivers work in different parts of the hospital.

Related Links:
Siemens Healthineers

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Signs of multiple sclerosis show up in blood years before symptoms appear (Photo courtesy of vitstudio/Shutterstock)

Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset

Autoimmune diseases such as multiple sclerosis (MS) are thought to occur partly due to unusual immune responses to common infections. Early MS symptoms, including dizziness, spasms, and fatigue, often... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: A new study has identified patterns that predict ovarian cancer relapse (Photo courtesy of Cedars-Sinai)

Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse

High-grade serous ovarian carcinoma is the most lethal type of ovarian cancer, and it poses significant detection challenges. Typically, patients initially respond to surgery and chemotherapy, but the... Read more